Evidence map›Paper›PMID 42051258›Full record

ArticleFrontiers in pharmacology2026

Machine-learning CT radiomics for prognostication in unresectable pancreatic cancer.

Wenqi He, Chun Cao, Qi Li, Ruoxue Yang, Xuan Yu, Wei Wang, Youqiang Hu, Ping Jiang, Min Luo

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenqi He *Department of Radiology, Zigong Fourth People's Hospital, Zigong, China.
Chun Cao *Department of Oncology, Zigong First People's Hospital, Zigong, China.
Qi LiDepartment of Oncology, Affiliated Santai Hospital of North Sichuan Medical College, Mianyang, China.
Ruoxue YangThe First Clinical College, Chongqing Medical University, Chongqing, China.
Xuan YuState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Wei WangDepartment of Radiology, Zigong Fourth People's Hospital, Zigong, China.
Youqiang HuDepartment of Radiology, Zigong Fourth People's Hospital, Zigong, China.
Ping JiangDepartment of Radiology, Zigong Fourth People's Hospital, Zigong, China.
Min LuoDepartment of Radiology, Zigong Fourth People's Hospital, Zigong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We aimed to develop an interpretable radiomics-clinical model to predict overall survival (OS) in unresectable pancreatic cancer (PC). Methods: In this retrospective cohort, 202 patients with unresectable PC were enrolled. A total of 1,130 radiomics features were extracted from a region of interest encompassing the largest primary lesion using 3D-Slicer. Least absolute shrinkage and selection operator (LASSO)-selected features associated with OS were used to construct a radiomics risk score (RS). Independent clinical predictors were identified through stepwise Cox regression. A nomogram integrating RS with independent clinical predictors was built. Results: Median OS (mOS) for the entire cohort was 20.3 months. From 1,130 baseline CT radiomics features, LASSO retained 12 prognostic descriptors, which were linearly combined to compute a radiomics RS. Stepwise Cox regression identified age, sex, and CA19-9 as independent clinical predictors. A nomogram integrating RS with these variables was constructed in the training set. In the validation set, the area under the receiver operating characteristic curve (AUC) reached 0.804, 0.812, and 0.794 for 1-, 2-, and 3-year OS, respectively. Conclusion: An interpretable radiomics-clinical nomogram provided accurate survival prediction in unresectable pancreatic cancer.

Indexed as

CTimmunotherapymachine-learningpancreatic cancerradiomicsradiotherapy

Identifiers

PMID42051258
PMCPMC13111434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.